688 related articles for article (PubMed ID: 22978645)
1. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
[TBL] [Abstract][Full Text] [Related]
4. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
[TBL] [Abstract][Full Text] [Related]
5. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
6. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.
Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Angelberger S; Novacek G; Mikulits A; Vogelsang H; Reinisch W
Eur J Clin Invest; 2011 Oct; 41(10):1071-6. PubMed ID: 21413978
[TBL] [Abstract][Full Text] [Related]
7. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases.
Papay P; Eser A; Winkler S; Frantal S; Primas C; Miehsler W; Novacek G; Vogelsang H; Dejaco C; Reinisch W
Inflamm Bowel Dis; 2011 Jan; 17(1):84-90. PubMed ID: 20722065
[TBL] [Abstract][Full Text] [Related]
8. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
[TBL] [Abstract][Full Text] [Related]
9. Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
Amorim RF; Viegas ERC; Carneiro AJV; Esberard BC; Chinem ES; Correa RS; Rodrigues L; Ribeiro-Alves M; Silva KS; de Souza HS; Carvalho ATP
Dig Dis Sci; 2019 Jul; 64(7):1916-1922. PubMed ID: 30673986
[TBL] [Abstract][Full Text] [Related]
10. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.
Wyndham-Thomas C; Dirix V; Schepers K; Martin C; Hildebrand M; Goffard JC; Domont F; Libin M; Loyens M; Locht C; Van Vooren JP; Mascart F
BMC Infect Dis; 2015 Feb; 15():59. PubMed ID: 25886172
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
[TBL] [Abstract][Full Text] [Related]
12. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
[TBL] [Abstract][Full Text] [Related]
13. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
[TBL] [Abstract][Full Text] [Related]
14. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
15. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
[TBL] [Abstract][Full Text] [Related]
16. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease.
Hradsky O; Ohem J; Zarubova K; Mitrova K; Durilova M; Kotalova R; Nevoral J; Zemanova I; Dryak P; Bronsky J
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):320-4. PubMed ID: 24126833
[TBL] [Abstract][Full Text] [Related]
17. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease.
Schoepfer AM; Flogerzi B; Fallegger S; Schaffer T; Mueller S; Nicod L; Seibold F
Am J Gastroenterol; 2008 Nov; 103(11):2799-806. PubMed ID: 18684188
[TBL] [Abstract][Full Text] [Related]
18. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay.
Torres Costa J; Sá R; Cardoso MJ; Silva R; Ferreira J; Ribeiro C; Miranda M; Plácido JL; Nienhaus A
Eur Respir J; 2009 Dec; 34(6):1423-8. PubMed ID: 19948911
[TBL] [Abstract][Full Text] [Related]
20. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
